XML 20 R12.htm IDEA: XBRL DOCUMENT v3.23.2
Revenues
 6 Months Ended
Jun. 30, 2023
Revenue from Contract with Customer [Abstract]  
Revenues Revenues
We operate in one business segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues by product and by geographic area, based on customers’ locations, are presented below. The majority of ROW revenues relates to products sold in Europe.
Revenues were as follows (in millions):
Three months ended June 30,
20232022
U.S.ROWTotalU.S.ROWTotal
Prolia$691 $337 $1,028 $611 $311 $922 
ENBREL1,055 13 1,068 1,036 15 1,051 
XGEVA387 143 530 391 142 533 
Otezla495 105 600 487 107 594 
Repatha212 212 424 154 171 325 
Aranesp123 242 365 132 225 357 
KYPROLIS234 112 346 213 104 317 
Nplate176 134 310 156 128 284 
EVENITY192 89 281 130 61 191 
Other products(1)
1,171 560 1,731 1,136 571 1,707 
Total product sales(2)
$4,736 $1,947 6,683 $4,446 $1,835 6,281 
Other revenues303 313 
Total revenues$6,986 $6,594 
Six months ended June 30,
20232022
U.S.ROWTotalU.S.ROWTotal
Prolia$1,314 $641 $1,955 $1,193 $581 $1,774 
ENBREL1,619 28 1,647 1,879 34 1,913 
XGEVA771 295 1,066 759 276 1,035 
Otezla789 203 992 837 208 1,045 
Repatha409 403 812 319 335 654 
Aranesp238 482 720 269 446 715 
KYPROLIS468 236 704 409 195 604 
Nplate422 250 672 312 238 550 
EVENITY356 179 535 240 121 361 
Other products(1)
2,325 1,101 3,426 2,266 1,095 3,361 
Total product sales(2)
$8,711 $3,818 12,529 $8,483 $3,529 12,012 
Other revenues562 820 
Total revenues$13,091 $12,832 
____________
(1)    Consists of product sales of our non-principal products as well as our Bergamo and Gensenta subsidiaries.
(2)    Hedging gains and losses, which are included in product sales, were not material for the three and six months ended June 30, 2023 and 2022.